Multicenter comparison of first salvage chemotherapy versus novel therapy regimens in adult relapsed/refractory acute lymphoblastic leukemia

Ochs, Madeleine A.; Marini, Bernard L.; Benitez, Lydia; Stump, Sarah E.; Weis, Taylor M; Buhlinger, Kaitlyn; Diaz, Thomas; Reid, Justin H; Muluneh, Benyam; Pettit, Kristen; Burke, Patrick W.; Bixby, Dale

doi:10.1080/10428194.2022.2053530

Cited by 1 publication

(1 citation statement)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 91 In a Canadian trial comparing the efficacy of chemotherapy with new drugs like blinatumomab or inotuzumab in patients with R/R ALL when first resuscitation, CNS relapse rates were significantly lower in the new drug group than chemotherapy group (new therapy: 2.9% vs chemotherapy: 20.9%, P = .036), with OS rates and CR/CR with incomplete blood count recovery rates being similar in both groups. 93 Based on this study, novel therapies such as blinatumomab or inotuzumab may be beneficial in CNS prophylaxis. However, more large, prospective trials are necessary to demonstrate whether new therapies are beneficial in lowering CNSL recurrence.…”

Section: Prevention and Treatmentmentioning

confidence: 92%

Diagnosis and management of adult central nervous system leukemia

Liu,

Wang

2023

Blood Science

View full text Add to dashboard Cite

Central nervous system leukemia (CNSL) is a prominent infiltration reason for therapy failing in acute leukemia. Recurrence rates and the prognosis have alleviated with current prophylactic regimens. However, the accurate stratification of relapse risk and treatment regimens for relapsed or refractory patients remain clinical challenges yet to be solved. Recently, with hematopoietic stem cell transplantation (HSCT) and chimeric antigen receptor-T (CAR-T) cellular therapy showing encouraging effects in some CNSL patients, advances in treating CNSL have already been reported. The development of molecular targeted agents as well as antibody-based drugs will provide patients with more personalized treatment. This article summarized recent research developments about risk factors, diagnosis, prevention, and treatment in adults with CNSL.

show abstract

Section: Prevention and Treatmentmentioning

confidence: 92%